Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025 ...

Eli Lilly has shared positive results from a Phase II clinical trial (NCT06230523) evaluating eloralintide, an investigational once-weekly, selective amylin receptor, in adults with obesity or ...

Get the latest on MindMed’s Q3 2025 earnings: clinical trial milestones, financial strength, and pivotal Phase III data readouts expected in 2026.

Continued focused execution of RLY-2608 clinical trials in PI3Kα-mutated breast cancer and vascular malformations ...

Is the health care system financially sustainable? When the HFMA asked industry experts, the answer was a resounding "no." ...

Q3 2025 Management View CEO Robert I. Blum described the quarter as “highly productive and defining,” emphasizing “significant progress across the company's priority objectives” as Cytokinetics ...

Q3 2025 Management View CEO C. Mills emphasized Elutia's mission of "humanizing medicine so that patients can thrive without compromise," spotlighting the company's strategic focus on breast ...

The healthcare industry is buzzing with the transformative potential of artificial intelligence (AI) and machine learning (ML). However, amid the hype, a major sticking point is often overlooked: the ...

Lumonus, a leader in AI powered radiation oncology workflow solutions, today announced the close of its A$25 million Series B financing round. The round was led by Aviron Investment Management with ...

AEP: American Electric Power (NASDAQ: AEP); a regulated electric utility focused on transmission and power generation ...

Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseasesInitiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerabilit ...

Anika Therapeutics, Inc. (NASDAQ: ANIK) Q3 2025 Earnings Call Transcript November 5, 2025 Anika Therapeutics, Inc. misses on ...